Connective Tissue Gene Tests (CTGT) has added 12 new assays to its menu of molecular diagnostics for inherited disorders affecting connective tissues.
The Allentown, Pa.-based company is now offering microarray, Sanger sequencing, and next-generation sequencing-based tests for genes associated with Adams-Oliver syndrome, cerebral cavernous malformations, cutis laxa, multiple self-healing squamous epithelioma, opsismodysplasia, and supervalvular aortic stenosis.
The pricing of CTGT's new tests depends on the technology used and the number of genes assessed. For its array-based tests, the company relies on its High-Density Targeted Array platform, an Agilent Technologies-manufactured chip for copy number variation detection.